Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Conway

Showing results (91-100 of 146) with videos related to

Pageof 15
Sort By:
Journal of the International AIDS Society|November 9, 2017
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in CanadaSahar Saeed, Erin C Strumpf, Erica Em Moodie, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trialsAshley Brown, Tania M Welzel, Brian Conway, et al.
BMC Medical Research Methodology|August 12, 2022
Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learningGayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
HIV Clinical Trials|August 22, 2014
Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trialMarina B Klein, Terry Lee, Marie-Josée Brouillette, et al.
Journal of Viral Hepatitis|December 11, 2020
Distinct Hepatitis B and HIV co-infected populations in CanadaCurtis Cooper, Matt Driedger, David Wong, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|April 30, 2003
Drug Resistance Mutations in HIV-1Richard T. D'Aquila, , Jonathan M. Schapiro, et al.
Canadian Liver Journal|August 22, 2022
Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective studyBrian Conway, Julie Bruneau, Curtis Cooper, et al.
Pageof 15

Showing results (91-100 of 146) with videos related to

Sort By:
Pageof 15
Journal of the International AIDS Society|November 9, 2017
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in CanadaSahar Saeed, Erin C Strumpf, Erica Em Moodie, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 24, 2003
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trialsAshley Brown, Tania M Welzel, Brian Conway, et al.
BMC Medical Research Methodology|August 12, 2022
Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learningGayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, et al.
Drug and Alcohol Dependence|December 12, 2018
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studiesGraham R Foster, Gregory J Dore, Stanley Wang, et al.
HIV Clinical Trials|August 22, 2014
Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trialMarina B Klein, Terry Lee, Marie-Josée Brouillette, et al.
Journal of Viral Hepatitis|December 11, 2020
Distinct Hepatitis B and HIV co-infected populations in CanadaCurtis Cooper, Matt Driedger, David Wong, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|April 30, 2003
Drug Resistance Mutations in HIV-1Richard T. D'Aquila, , Jonathan M. Schapiro, et al.
Canadian Liver Journal|August 22, 2022
Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective studyBrian Conway, Julie Bruneau, Curtis Cooper, et al.
Pageof 15